Dogs with allergic dermatitis (food, flea, environmental) often endure intense itching, redness, chewing/licking of skin, and recurrent infections. Two oral medications that target this problem are Zenrelia and Apoquel. They share similarities but also have important differences in their mechanisms, dosing, safety concerns and practical use.
What each drug is / approved for
Apoquel
- The active ingredient is Oclacitinib.
- Apoquel is approved for dogs at least 12 months old for the control of pruritus (itching) associated with allergic dermatitis and the control of atopic dermatitis.
- It’s been on the market for a while (since ~2013 in the U.S.).
- Mechanism: it’s a Janus kinase (JAK) inhibitor (primarily JAK1) that disrupts itch- and inflammation-related signalling.
Zenrelia
- The active ingredient is Ilunocitinib (brand name Zenrelia).
- Zenrelia is also approved for dogs at least 12 months old for the control of pruritus associated with allergic dermatitis and the control of atopic dermatitis.
- Recently approved (in 2024 in the U.S.).
- Also a JAK inhibitor, but with some differences in specificity and other details.
Key differences
Here are several important comparisons:
|
Feature |
Apoquel |
Zenrelia |
|
Active ingredient |
Oclacitinib (JAK1-selective) |
Ilunocitinib (non-selective JAK inhibitor: JAK1, JAK2, TYK2) |
|
Dosing regimen |
Typically: twice a day for first ~14 days, then once daily for maintenance. |
Once daily (0.6-0.8 mg/kg) from the start. |
|
Time to relief |
Rapid: relief of itch often within hours; significant improvement within 24 hours. |
Also rapid; studies show significant relief, and some claims of similar or better efficacy over time compared to Apoquel. |
|
Vaccine / immune safety concerns |
Use with vaccines is generally allowed; vaccine warning less prominent in label. |
Has a boxed warning regarding risk of inadequate immune response to vaccines; dogs must be up to date with vaccinations and delay starting or stop before/after vaccination. |
|
Side-effect / risks profile |
Known side effects: GI upset (vomit/diarrhea), lethargy, possible increased risk of infections, and possible neoplastic conditions. |
Similar risks of immunosuppression, infections, new neoplastic conditions; plus the specific warning about vaccine response. |
|
Cost / market position |
Established product, many veterinarians experienced with it |
Newer entrant; may be positioned (by manufacturer) as once-daily, cheaper alternative. |
Practical considerations for pet owners
Here are some things you and your veterinarian should consider when deciding between these options:
- Diagnosis first: Make sure the dog’s itching is truly due to allergic dermatitis/atopic dermatitis, and that other causes (parasites, infections, food allergy, fleas) are addressed.
- Vaccination status: With Zenrelia, you’ll need to ensure the dog is up-to-date with vaccines before starting, and avoid live or certain vaccines during treatment. With Apoquel, that particular restriction is not as stringent.
- Monitoring for infections or cancer: Because both drugs suppress parts of the immune system, you’ll want regular check-ups, and monitor for any new lumps or infections.
- Long-term use: Many dogs will need lifelong management of their allergies — the drug is not a cure for the underlying allergic tendency. As noted in the literature for Zenrelia: “atopic dogs are not ever cured but rather managed.”
- Cost & ease of dosing: Because Zenrelia is once daily from the start, it might be more convenient. But cost may vary and availability in your country (Australia) may differ.
Which one might be “better”?
There’s no absolute winner — it depends on the dog, the allergy severity, budget, vaccine status, and how your vet weighs risks vs benefits. But here are some rough guidelines:
- If your dog needs rapid itch relief, and you have good vet support, Apoquel has longer track-record and well-known dosing.
- If your dog has had partial or lost response to Apoquel, or you prefer once-daily convenience, and the vaccine-issue is manageable, Zenrelia might be a good alternative.
- If your dog is scheduled for vaccination soon or cannot delay vaccines, you may prefer Apoquel given the stricter vaccination constraint with Zenrelia.
Safety & Warning Summary
- Zenrelia: Boxed warning about vaccine interactions, risk of vaccine-induced disease in some dogs in studies. Also warning about opportunistic infections, new neoplasia, hematologic effects.
- Apoquel: Less strict vaccine requirement, but still immune-suppressive risks: infections, demodicosis, possible cancer risks in long-term use.
- Both should not be used in dogs with serious infection, or in puppies <12 months.
- Both require vet supervision, and ideally periodic check-ups / bloodwork if long-term.
- Both are prescription only, and usage must be tailored by a vet.
Conclusion
In summary: Zenrelia and Apoquel are both valuable tools in managing allergic skin disease in dogs. They share a class (JAK inhibitors), similar indications, but differ in active molecule, dosing regimen, vaccine precautions, and relative novelty. The “right” choice depends on your dog’s specific situation: how badly they’re scratching, prior response to treatments, cost, convenience, vaccination status, and how much monitoring you’re willing to do.
If you’re considering switching or starting one of these, talk openly with your vet about:
- What relief you expect (timeline, extent)
- Risks (immune suppression, infections, cancer risk)
- Vaccination schedule and any upcoming vaccines
- Cost, availability, and long-term plan (will this be lifelong?)
- What other allergy-management steps you’ll use (fleas, diet, environment, baths) — because the medication works with those, not instead of them.
Disclaimer: This article is for informational purposes only and does not constitute veterinary advice. Always consult your veterinarian before starting or changing your dog’s medication or treatment plan.
